Provided by Tiger Trade Technology Pte. Ltd.

Nyxoah SA

1.49
-0.0700-4.49%
Post-market: 1.48-0.0099-0.66%19:36 EDT
Volume:79.72K
Turnover:120.50K
Market Cap:151.98M
PE:-0.60
High:1.54
Open:1.54
Low:1.49
Close:1.56
52wk High:6.87
52wk Low:1.26
Shares:102.00M
Float Shares:52.65M
Volume Ratio:0.69
T/O Rate:0.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4672
EPS(LYR):-2.7756
ROE:-122.68%
ROA:-36.87%
PB:1.58
PE(LYR):-0.54

Loading ...

Company Profile

Company Name:
Nyxoah SA
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
154
Office Location:
Rue Edouard Belin 12,Mont-Saint-Guibert,Walloon Brabant,Belgium
Zip Code:
1435
Fax:
32 1 045 90 75
Introduction:
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Directors

Name
Position
Olivier Taelman
Chief Executive Officer and Executive Director
Robert Taub
Chairman of the Board and Non-Executive Director
Daniel Wildman
Non-Executive Director
Jurgen Hambrecht
Non-Executive Director
Kevin Rakin
Non-Executive Director
Pierre Gianello
Non-Executive Director
Rita Johnson Mills
Non-Executive Director
Virginia Kirby
Non-Executive Director

Shareholders

Name
Position
Olivier Taelman
Chief Executive Officer and Executive Director
John Landry
Chief Financial Officer
Bruno Onkelinx
Chief Technology Officer
Scott Holstine
Chief Commercial Officer